XBIT: XBiotech Inc. Stock

by  •  • Comments Off on XBIT: XBiotech Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 212.33
Enterprise Value ($M) 39.21
Book Value ($M) 192.12
Book Value / Share 6.31
Price / Book 1.11
NCAV ($M) 167.30
NCAV / Share 5.49
Price / NCAV 1.27

Profitability (mra)
Return on Invested Capital (ROIC) -0.16
Return on Assets (ROA) -0.14
Return on Equity (ROE) -0.15

Liquidity (mrq)
Quick Ratio 11.57
Current Ratio 11.57

Balance Sheet (mrq) ($M)
Current Assets 185.03
Assets 209.85
Liabilities 17.74
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-07 13G/A Mckenzie W Thorpe 9.68 -2.14
02-07 13G/A Simard John 19.90 27.31
02-07 13G/A Gut Thomas 12.86 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-01 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION R
2024-04-24 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION R
2024-03-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ Transaction Report pursuant to Sect

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-15 12,912 87,126 14.82
2024-11-14 12,413 51,663 24.03
2024-11-13 4,211 27,101 15.54
2024-11-12 13,398 43,842 30.56
2024-11-11 13,876 47,075 29.48

(click for more detail)

Similar Companies
VTRS – Viatris Inc. VTYX – Ventyx Biosciences, Inc.
VYGR – Voyager Therapeutics, Inc. XERS – Xeris Biopharma Holdings, Inc.
XLO – Xilio Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io